TIDMEVG

RNS Number : 6836W

Evgen Pharma PLC

18 April 2019

Evgen Pharma plc

("Evgen Pharma", or the "Company")

Posting of Circular

and

Timing of General Meeting

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that further to its announcement of the Placing yesterday (the "Placing Announcement"), a shareholder circular, including the notice of General Meeting, and a form of proxy are today being posted to shareholders. The shareholder circular and notice of General Meeting will be made available on the Company's website www.evgen.com

Furthermore, since the posting of the Placing Announcement yesterday, the timing of the General Meeting has been changed and will now take place on 8 May 2019 at 11.00 a.m. at the offices of finnCap, 60 New Broad Street, London EC2M 1JJ.

Capitalised terms used in this announcement shall have the same meanings as the definitions in the Placing Announcement.

For further information please visit www.evgen.com or contact:

 
 Evgen Pharma plc                                c/o +44 (0) 20 7466 5000 
  Dr Stephen Franklin, CEO 
  Richard Moulson, CFO 
  www.evgen.com 
 finnCap 
  Geoff Nash, Teddy Whiley (Corporate 
  Finance) 
  Alice Lane, Manasa Patil (ECM) 
  www.finncap.com                                    +44 (0) 20 7220 0500 
 WG Partners LLP 
  Nigel Barnes, Claes Spång                     +44 (0) 20 3705 9330 
 Buchanan 
  Mark Court, Sophie Wills, Tilly 
  Abraham 
  evgen@buchanan.uk.com                              +44 (0) 20 7466 5000

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBSGDSCDBBGCI

(END) Dow Jones Newswires

April 18, 2019 12:30 ET (16:30 GMT)

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Evgen Pharma
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Evgen Pharma